ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1070

CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE

Sarit sekhar Pattanaik1, Aditya kumar Panda2, Rashmi ranjan Sahoo1, Rina Tripathy3 and Bidyut kumar Das1, 1Medicine, SCB Medical College, Cuttack, India, 2Centre for Life science, Central University of Jharkand, Ranchi, India, 3Biochemistry, SCB Medical College, Cuttack, India

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: biomarkers and nephritis, Disease Activity, SLE

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Genetics, Gene Expression, and Epigenetics

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:
Cluster of differentiation 14 (CD14) plays an important role in innate
immune system as a co-receptor in TLRs (2, 4, 7 and 9) signaling. Host innate
receptor TLR7 and 9 recognizes nucleic acids as a ligand and produce type I IFN
which is believed to be associated in the pathogenesis of SLE.  TLR7 and 9
require CD14 for effective signaling, we hypothesized that CD14 polymorphism
and soluble CD14 levels would correlate with disease susceptibility and disease
activity  in SLE.

 Methods: In
a case control hospital based study, 130 female SLE patients fulfilling the ACR
criteria and 140 age, sex matched healthy controls were enrolled. CD14 (C-159T)
polymorphism was genotyped by PCR-RFLP.   In 78 SLE patients and 46 healthy
controls plasma sCD14, TNF-α, IFN-α levels were quantified by ELISA. Clinical,
serological and other markers of disease activity (C3, C4 and anti-dsDNA) were
measured by standard laboratory procedures.

Results: Prevalence
of mutant genotypes (CT and TT) and allele T were significantly higher in
patients of SLE. Mutants (CT and TT) for CD14(C-159T) polymorphism were
associated with higher plasma sCD14, IFN-α and TNF-α compared to wild
type CC. Plasma sCD14 levels were significantly high in SLE patients compared
to healthy controls (P<0.001).Plasma sCD14 correlated with SLEDAI(P = 0.002,
r = 0.34), proteinuria (P=0.001, r = 0.34) and negatively correlated with C3 (P
= 0.003, r = -0.33) and C4 (P < 0.0001, r = -0.50). Patients with lupus
nephritis displayed higher plasma levels of sCD14, and IFN-α

Conclusion: CD14
(C-159T) polymorphism is associated with SLE. Higher soluble CD14 levels is
significantly associated with SLE disease activity and lupus nephritis making
it a promising biomarker.

 

Association
of CD14(C-159T) polymorphism with plasma sCD14, IFN-α and TNF-α
.

Plasma
concentrations (mean ± standard error of mean) of sCD14, IFN-α and TNF-α
were measured by commercial kit. Plasma of 78 SLE patients were quantified for sCD14
(A), IFN-α (B) and TNF-α (C) and correlated with CD14(C-159T)
polymorphism. Numbers of samples from each genotype are shown in box. Mean
plasma levels in different genotypes were compared by Kruskal-Wallis test
followed by Dunns post test.  P value less than 0.05 was considered as
significant. *P<0.05, **P<0.01, ***P<0.001

 

 

 

 

 

 

 


Disclosure: S. S. Pattanaik, None; A. K. Panda, None; R. R. Sahoo, None; R. Tripathy, None; B. K. Das, None.

To cite this abstract in AMA style:

Pattanaik SS, Panda AK, Sahoo RR, Tripathy R, Das BK. CD 14(C-159T) Polymorphism and Soluble CD14 Are Associated with Increased Disease Activity and Nephritis in SLE [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/cd-14c-159t-polymorphism-and-soluble-cd14-are-associated-with-increased-disease-activity-and-nephritis-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cd-14c-159t-polymorphism-and-soluble-cd14-are-associated-with-increased-disease-activity-and-nephritis-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology